Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

References

• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Multiple Myeloma. Version 3; 2016 [cited 2016 Feb 2]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254.
   PubMed Web of Science ®Google Scholar
• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765. doi:10.1200/JCO.2008.20.8983.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel JF, Ludwig H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi133–vi137. doi:10.1093/annonc/mdt297.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600. doi:10.1200/JCO.2013.48.7934.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520. doi:10.1182/blood-2007-10-116129.
   PubMed Web of Science ®Google Scholar
• Kumar L, Verma R, Radhakrishnan VR. Recent advances in the management of multiple myeloma. Natl Med J India. 2010;23:210–218.
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375–4382. doi:10.1182/blood-2011-11-395749.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Richardson PG, Laubach JP, et al. Management of relapsed multiple myeloma after autologous stem cell transplant. Biol Blood Marrow Transplant. 2015;21:793–798. doi:10.1016/j.bbmt.2014.12.026.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157. doi:10.1038/leu.2011.196.
   PubMed Web of Science ®Google Scholar
• Ninlaro (ixazomib) Prescribing Information. Cambridge, MA: Takeda Pharmaceutical Company Limited; 2015 [cited 4 Mar 2016]. Available from: https://www.ninlarohcp.com/prescribing-information.pdf.
   Google Scholar
• Farydak (panobinostat) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2016 [cited 4 Mar 2016]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/farydak.pdf.
   Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–2715. doi:10.1056/NEJMra072739.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23:viii6–viii9. doi:10.1093/annonc/mds256.
   PubMed Web of Science ®Google Scholar
• Luptakova K, Avigan D. Immune therapy in multiple myeloma. Clin Adv Hematol Oncol. 2015;13:767–775.
   PubMedGoogle Scholar
• Darzalex (daratumumab) Prescribing information. Horsham (PA): Janssen Biotech, Inc.; 2015 [cited 4 Mar 2016]. Available from: http://www.darzalex.com/shared/product/darzalex/darzalex-prescribing-information.pdf.
   Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560. doi:10.1016/S0140-6736(15)01120-4.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof I, et al. Immunomodulatory effects and adaptive response to daratumumab in multiple myeloma. Blood. 2015;126:3037. [abstract]
   Google Scholar
• Raab M, Goldschmidt H, Agis H, et al. A phase I/IIa Study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma. J Clin Oncol. 2015;33(suppl):8574. [abstract]
   Google Scholar
• Empliciti (elotuzumab) prescribing Information. Princeton (NJ): Bristol-Myers Squibb; 2015 [cited 4 Mar 2016]. Available from: http://packageinserts.bms.com/pi/pi_empliciti.pdf.
   Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784. doi:10.1158/1078-0432.CCR-07-4246.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Phase III Study of lenalidomide and dexamethasone with and without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma. 2015 [cited 2016 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT01335399?term=01335399&rank=1.
   Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337. doi:10.1182/blood-2007-08-107292.
   PubMed Web of Science ®Google Scholar
• Glavey S, Reagan M, Manier S, et al. Dissecting the mechanisms of activity of SLAMF7 and the targeting antibody elotuzumab in multiple myeloma. Blood. 2014;124:3431.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–1849. doi:10.1007/s00262-013-1493-8.
   PubMed Web of Science ®Google Scholar
• Guo H, Cruz-Munoz ME, Wu N, et al. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring Src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol. 2015;35:41–51. doi:10.1128/MCB.01107-14.
   PubMed Web of Science ®Google Scholar
• Lonial S, Kaufman JL, Laubach J, et al. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13:1731–1740. doi:10.1517/14712598.2013.847919.
   PubMed Web of Science ®Google Scholar
• Bezman N, Kearney A, Praveen P, et al. Differential effects of elotuzumab (anti-SLAMF7) and anti-CD38 monoclonal antibodies in preclinical models. Haematologica. 2016;101:[P646].
   Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–559. doi:10.1182/blood-2011-06-360552.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30:1960–1965. doi:10.1200/JCO.2011.37.7069.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953–1959. doi:10.1200/JCO.2011.37.2649.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab in combination with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase 1b study. Clin Lymphoma Myeloma Leuk. 2016;16:129–138.
   PubMed Web of Science ®Google Scholar
• Berenson J, Swift R, Hobson S, et al. Elotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone in patients with multiple myeloma: a phase 2 safety study. J Oncol Pharm Pract. 2016;22:22–3[CT31].
   Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2:e516–e527.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pegourie B, et al. A randomized, open-label, Phase 2 study of bortezomib and dexamethasone with and without elotuzumab in patients with relapsed/refractory multiple myeloma. The 20th Congress of the European Hematology Association (EHA); 2015 June 11–14; Vienna, Austria, The European Hematology Association (EHA), S103 [Oral].
   Google Scholar
• Palumbo A, Offidani M, Pegourie B, et al. Elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: 2-year follow-up. Blood. 2015;126:510. [abstract]
   Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. ELOQUENT-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma - 3-year safety and efficacy follow-up. Blood. 2015;126:2093. [abstract]
   Google Scholar
• Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116:3807–3814. doi:10.1002/cncr.25139.
   PubMed Web of Science ®Google Scholar
• Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90:429–439. doi:10.1007/s00277-010-1080-4.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pegourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127:2833–2840. doi:10.1182/blood-2016-01-694604.
   PubMed Web of Science ®Google Scholar
• Poulart V, Jou Y-M, Delmonte T, et al. Fc-gamma receptor polymorphisms and progression-free survival: analysis of three clinical trials of elotuzumab in multiple myeloma. Haematologica. 2016;101:[E1281].
   Web of Science ®Google Scholar
• Genzen JR, Kawaguchi KR, Furman RR. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol. 2011;155:123–125. doi:10.1111/j.1365-2141.2011.08644.x.
   PubMed Web of Science ®Google Scholar
• McCudden CR, Voorhees PM, Hainsworth SA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem. 2010;56:1897–1899. doi:10.1373/clinchem.2010.152116.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Otten HG, El HO, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016;54:1105–1109. doi:10.1515/cclm-2015-0888.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Lonial S, Casado LF, et al. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2015;15:e267–e268. doi:10.1016/j.clml.2015.07.561.
   Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. ELOQUENT-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma - 3-year safety and efficacy follow-up. 57th Annual Meeting & Exposition of American Society of Hematology (ASH); 2015 December 5–8; Orlando (FL). [Oral #28]. [cited 2016 Mar 4]. Available from: http://www.myelomabeacon.com/docs/ash2015/28.pdf.
   Google Scholar
• ClinicalTrials.gov. S1211, bortezomib, dexamethasone, and lenalidomide with and without elotuzumab in treating patients with newly diagnosed high-risk multiple myeloma. 2015 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01668719?term=NCT01668719&rank=1.
   Google Scholar
• ClinicalTrials.gov. A Phase I open label study of the safety and tolerability of elotuzumab (BMS-901608) administered in combination with either lirilumab (BMS-986015) or urelumab (BMS-663513) in subject with multiple myeloma (Study 028) (NCT02252263). 2015 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02252263?term=02252263&rank=1.
   Google Scholar
• ClinicalTrials.gov. Japanese study of (BMS-901608) (elotuzumab) in combination with lenalidomide and low dose dexamethasone. 2015 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01241292.
   Google Scholar
• ClinicalTrials.gov. Elotuzumab in autologous stem cell transplantation (ASCT) and lenalidomide maintenance for multiple myeloma. 2016 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02655458?term=NCT02655458&rank=1.
   Google Scholar
• ClinicalTrials.gov. Study of elotuzumab with lenalidomide as maintenance after autologous stem cell transplant (ASCT). 2015 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02420860?term=NCT02420860&rank=1.
   Google Scholar
• ClinicalTrials.gov. Study of bortezomib, lenalidomide, dexamethasone & elotuzumab in newly diagnosed MM. 2015 [cited 2016] Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02375555?term=NCT02375555&rank=1
   Google Scholar
• ClinicalTrials.gov. Safety study of elotuzumab in combination with thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. 2015 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01632150?term=NCT01632150&rank=1.
   Google Scholar
• ClinicalTrials.gov. Trial of elotuzumab with or without pomalidomide and low-dose dexamethasone to treat refractory and relapsed and refractory multiple myeloma. 2015 [cited 2016 Feb 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02654132?term=NCT02654132&rank=1.
   Google Scholar
• ClinicalTrials.gov. A study of Elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd) in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide (Study 142) (NCT02612779). 2015 [cited 2016 Mar 4]. Available from: https://www.clinicaltrial.gov/ct2/show/NCT02612779?term=02612779&rank=1
   Google Scholar
• ClinicalTrials.gov. Biomarker study of elotuzumab in high risk smoldering myeloma. 2015 [cited 2016] Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01441973?term=NCT01441973&rank=1.
   Google Scholar
• ClinicalTrials.gov. Trial of combination of elotuzumab and lenalidomide ± dexamethasone in high-risk smoldering multiple myeloma. 2015 [cited 2016. Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02279394?term=NCT02279394&rank=1.
   Google Scholar
• ClinicalTrials.gov. PH III study of lenalidomide and dexamethasone with and without elotuzumab to treat previously untreated multiple myeloma (ELO 1 Substudy). 2015 [cited 2016 Mar 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01891643?term=NCT01891643&rank=1.
   Google Scholar
• ClinicalTrials.gov. A Phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD6). 2015 [cited 2016 Mar 4]. Availablefrom: https://clinicaltrials.gov/ct2/show/NCT02495922?term=NCT02495922&rank=1.
   Google Scholar
• ClinicalTrials.gov. Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma (CheckMate 602) (NCT02726581). 2016 [cited 2016 Apr 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02726581.
   Google Scholar
• Usmani SZ, Sexton R, Ailawadhi S, et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015;5:e334. doi:10.1038/bcj.2015.62.
   PubMed Web of Science ®Google Scholar
• EMA. Elotuzumab: Summary of product characteristics. 2016 [cited 2016 May 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf.
   Google Scholar